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Objectives: To evaluate the clinical characteristics among hypertension patients 
with dislipidemia in Shanghai, China. MethOds: The information of hypertensive 
patients who had detected their serum LDL-C was extracted from the Electronic 
Health Record (eHR) system in Minhang district, Shanghai. According to the LDL-C 
criteria of Chinese guidelines on prevention and treatment of dyslipidemia in 
adults (2007), LDL-C level was categorized into three subgroups: acceptable, < 3.37 
mmol/L; borderline, 3.37-4.12 mmol/L; and high  ≥ 4.12 mmol/L. Patients with either 
borderline or high LDL-C level were considered as dislipidemia. Information on 
demographics, life-style, medical records, as well as cardiovascular events was col-
lected. Hypertension was identified by ICD-10 code in the database. Results: A 
total of 6765 hypertensive patients with available LDL-C measurement were ana-
lyzed. Among these patients, 57.4% were females, 29.4% had dislipidemia. Mean age 
was 68.2 years old for hypertension patients with dislipidemia and 67.0 years old 
for those without dyslipidemia. The proportion of females in the two groups were 
68.6% vs. 52.6%; smoking 13.3% vs, 19.5%; and drinking 16.1% vs. 22.3%; respectively. 
Moreover, hypertension patients with dislipidemia had slightly higher obesity (17.0% 
vs. 16.1%), grade 3 hypertension (21.0% vs. 19.1%), fasting blood glucose (36.8% vs. 
30.9%) and cardiovascular events rate (9.3% vs. 8.4%). cOnclusiOns: Hypertension 
patients with dislipidemia had more risk factors for cardiovascular disease than 
patients without dislipidemia.
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Objectives: Patients undergoing percutaneous coronary intervention (PCI) repre-
sent a group of patients with a high-risk of cardiovascular events. Limited informa-
tion exists in the literature on patient characteristics and drug treatments before 
and after PCI in China. The primary objective of this research was to assess the 
use of lipid-lowering and antiplatelet therapy prior to and post PCI. MethOds: 
We conducted a retrospective, observational study on all patients who underwent 
PCI at a large urban hospital in Shanghai, China from 05/2010 to 06/2011. Patient 
clinical and demographic characteristics were assessed; drug treatments, includ-
ing statin and antiplatelet therapy, were compared prior to and post PCI. Results: 
A total of 565 patients (80.5% male) had PCI during the study period and were 
included in the analysis. Both the mean and median age was 65 years old (range 
35 to 90). At baseline, 71.7% had angina, 66.0% had hypertension, 31.0% had dia-
betes, 20.4% had hyperlipidemic pancreatitis, 14.3% had a history of myocardial 
infarction, and 13.8% had chronic kidney disease. 55.0% of patients were active 
smokers or previously smoked and PCI was not the first time for 10.6% of patients. 
Prior to the current PCI, the majority of patients were on aspirin (95.8%) and clopi-
dogrel (99.8%), very few were on cilostazol (3.2%) and tirofiban (2.0%), and 70.6% 
of patients were on statins. The majority of patients (79.8%) received one stent 
with 20.2% of patients receiving two or more stents. Post PCI, the proportion of 
patients on statins increased significantly to 98.8% (p < 0.0001); there was little 
change in the proportion of patients on the other four drugs. cOnclusiOns: 
Patients who underwent PCI had significant prior comorbidities and risk factors 
of cardiovascular diseases. There was a significant increase in the proportion of 
patients on statins after PCI.
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Objectives: This research aims to have a trial calculation on the medical cost 
reduction for the patient group prescribed the combination drug of ARB and cal-
cium antagonist (a Combination Drug Group) against the patient group prescribed 
the combination use of ARB and calcium antagonist (a Combined Application 
Group). MethOds: We used the data of Japan Medical Data Center (JMDC), which 
provides health insurance claims data with linked health check-up data of 1.7 
million members from health insurance societies in Japan. Since the data is not 
based on randomized controlled trial, we adjusted confounding factors using pro-
pensity score analysis. Through the examination, we found that the propensity 
score can be modeled by logistic regression including following four variables: age, 
square of age, log of medical cost before index time and square of log of medical 
cost before index time. Results: As a result of our research, we estimated the 
adjusted average of medical cost for Combination Drug Group is lower by 900 
yen per a month than that for Combined Application Group, which represents 
1.7% of adjusted average monthly medical cost for Combined Application Group, 
52,100 yen. cOnclusiOns: Our research utilizing the real world data concluded 
that the combination drug of ARB and calcium antagonist can have a reductive, 
though limited, impact on the medical cost. Considering the general tendency 
that the medication cost itself of combination drug is higher than that of the 
combined use of drugs, we conclude that the result shows meaningful example 
of real world data analysis.
Objectives: To synthesis current evidence of the impact of Glucagon-like pep-
tide-1 receptor agonists (GLP-1 RA) on heart rate, blood pressure and hyperten-
sion. MethOds: Meta-analysis of available RCTs comparing GLP-1 RA with placebo 
and other active anti-diabetic drugs among patients with type 2 diabetes. Weighted 
mean differences between trial arms for changes in heart rate and blood pressure, 
and odds ratio of hypertension, after a minimum of 8-week follow-up. Results: 
42 trials with 12 treatments were included. Overall, liraglutide-1.2mg-once-daily 
and liraglutide-1.8mg-once-daily increased the heart rate by 2.47 (95% CI: 0.81 to 
4.09) and 2.95(95% CI: 1.44 to 4.46) beats/min (bpm) versus placebo, and with higher 
heart rate versus active control (range: 1.90 to 3.19). This effect was more evident 
for liraglutide and exenatide long-acting release than exenatide-twice-daily. GLP-1 
RA decreased systolic blood pressure with a range from -0.81(95% CI: -3.17, 1.51) to 
-4.42(95% CI: -2.87,-5.99) when compared to placebo, insulin and sulphanylureas. 
This effect was more evident for liraglutide than other kinds of GLP-1 RA. Statistical 
significance was only detected in reduction of diastolic blood pressure for exenatide-
10μ g-twice-daily versus placebo (-1.07 mmHg, 95% CI: -1.89,-0.26) and insulin (-1.35 
mmHg, 95% CI: -1.99,-0.65). In comparison to placebo and active control, no statis-
tically significant association between incident hypertension and GLP-1 RA was 
detected. cOnclusiOns: Our network meta-analysis from Bayesian analysis, for 
the first time, provided a useful and complete picture of the associations between 
GLP-1RA, conventional anti-diabetic drugs and placebo on heart rate, blood pres-
sure and hypertension. GLP-1 RA was associated with a slight increase in heart rate, 
modest reduction on blood pressure, yet no significant association with hyperten-
sion. However, further evidence is necessary for more conclusive inferences on 
mechanisms underlying the rise in heart rate and the reduction in blood pressure.
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Objectives: There have been controversies on the efficacy and safety of 
human insulin compared to animal insulin. The aim of this study was to com-
pare the efficacy and safety between human and animal insulin among Chinese 
patients. MethOds: A systematic literature search with key terms for identifying 
studies on human and animal insulin among Chinese population was performed 
using MEDLINE, China National Knowledge Infrastructure, Chinese Scientific 
Journals Database, Wan Fang database and Chinese Biological Medical Database. 
For each clinical outcome, meta-analysis was conducted when enough number of 
studies (≥ 3) meet inclusion criteria. Mean difference (MD) and risk ratio (RR) were 
pooled for continuous and count measurements, respectively. Results: A total of 
597 publications were retrieved and 21 studies were identified for inclusion, includ-
ing 7 randomized controlled trials (RCT), 5 non-randomized controlled trials (NRCT), 
and 9 studies where patients switched from animal insulin to human insulin (SW). 
Compared with animal insulin, human insulin was associated with significantly 
less daily dose, with MD(U/d) [CI] of -9.67 [-12.35,-6.99] for RCT, -9.19 [-10.01,-8.36] for 
NRCT, and -10.06 [-14.79,-5.33] for SW, as well as lower incidence of hypoglycemia, 
with RR of 0.29 [0.15,0.56] for RCT, 0.66 [0.51,0.86] for NRCT and 0.27 [0.11,0.67] for 
SW. In the analyses of RCTs, human insulin also had lower of local swelling and 
induration (RR: 0.09 [0.02, 0.39]) while the incidence difference of allergy was not 
statistically significant (RR: 0.19 [0.03, 1.09]). In addition, patients had significantly 
larger decrease of HbA1c when switching from animal insulin to human insulin with 
MD of -2.42% [-3.83, -1]. cOnclusiOns: Results from this meta-analysis suggest 
that human insulin may show more benefit on efficacy and safety among Chinese 
patients with diabetes compared to animal insulin. More detailed prospective stud-
ies are warranted to further explore this comparison.
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Objectives: In China, approximately 70% of insulin users utilize premix for-
mulations. This study was to evaluate premix use in China and the associated 
glycaemic outcomes in patients with Type 2 Diabetes Mellitus (T2DM). MethOds: 
Using the Adelphi™ T2DM Disease Specific Programme, we examined 279 patients 
aged ≥ 18years with T2DM receiving premix insulin. To examine the association 
between insulin dose and glycaemic control, we analyzed 140 patients whose dose 
was maintained for at least 3month longer than their HbA1c tests, without any 
insulin secretagogue use, and total daily insulin dose ≥ 0.2 units/kg according to 
the premix initial dose recommendation of the Chinese Diabetes Prevention and 
Treatment Guideline. A multivariate logistic regression adjusting for potential 
confounders was applied to assess the association. Results: Among 279 premix 
users, the mean (±SD) age was 58.3±11.8 years and 46.6% were male. The median 
(1st - 3rd quartile) time since diabetes diagnosis was 3 (2 - 6) years. Premix BID 
was used by most patients (76.7%), followed by premix QD (17.2%) and premix 
TID (6.1%). The median total daily insulin dose was 0.37 (0.18 - 0.53) units/kg. As 
recorded from the most recent HbA1c result, 36.0% of patients were in glycae-
mic control (HbA1c < 7%). A total of 140 patients were included in the analysis to 
examine the association between insulin dose and glycaemic control. The logistic 
regression revealed that for those patients taking total daily insulin of at least 0.2 
units/kg, the odds of being in better glycaemic control increased by a factor of 
1.31 for each additional 0.1 unit/kg of insulin therapy utilized [95% CI was (1.03, 
1.67), p= 0.029]. cOnclusiOns: This study indicates that under-dosing of premix 
insulin may be a factor contributing to sub-optimal glycaemic control among 
patients with T2DM in China. More detailed prospective studies are warranted to 
further explore this relationship.
